John M Hollander, PhD

Research Interests

The mitochondrion is an important organelle that is tasked with a multitude of functions requisite for cellular viability. As such, pathological influence on the mitochondrion remains at the forefront of research efforts focused on treating morbidity and mortality resulting from a multitude of disease states, including those influencing the cardiovascular system. Mechanistic evaluation of cardiovascular disease continues to suggest a central role for the mitochondrion, thus, understanding its contribution to the development and progression of cardiac pathologies is critical as we consider therapeutic options. The research in our laboratory focuses on understanding how different physiological and pathological states impact mitochondrial function, with the ultimate goal of developing therapeutic interventions designed to limit dysfunction to this critical organelle.

The Diabetic Heart

Diabetes mellitus is the world’s fastest growing disease with approximately 30 million people in the United States diagnosed and 84 million considered prediabetic (ADA). Cardiovascular complications including heart failure, remain the leading cause of mortality among diabetics. Our laboratory focuses on the development of treatments that can reduce bioenergetic deficits and contractile dysfunction associated with heart failure in diabetic patients through targeting interventions directed at the mitochondrion. Examination of mitochondria is complicated by the fact that two spatially-distinct mitochondrial subpopulations are present in the cardiac myocyte, interfibrillar mitochondria (IFM), which situate between the contractile proteins and subsarcolemmal mitochondria (SSM) that exist beneath the cell membrane. These spatially-distinct mitochondrial subpopulations appear to be influenced differently during cardiovascular pathologies, suggesting that subcellular spatial location is essential for understanding disease progression and needs to be considered when developing therapeutic intervention. Our laboratory utilizes diseased human patient samples, cell culture systems, and unique genetically-modified mouse models to develop and test therapeutic approaches for treating the diabetic heart. Cutting-edge genomic and proteomic techniques are utilized to bioinformatically identify targets for therapeutic intervention. Emphasis is placed on understanding the role of non-coding RNAs (miRNA, lncRNA, YRNA) and epigenetic modifications driving gene regulation.

Environmental Stressors

Increases in cardiovascular events and death have been linked to the inhalation of environmental toxicants. Environmental stressors include particulate matter from unintended sources (ultrafine, PM_2.5) and intended sources (engineered nanomaterial). Of particular concern are those that arise in the nanoscale range due to their increased surface area and physicochemical properties, which facilitate organ penetration. Despite their wide spread usage, it is unclear how particular matter exposure impacts human health from a consumer and occupational standpoint. Research from our laboratory indicates that acute and chronic exposure to engineered nanomaterials, negatively impacts cardiac contractile function and mitochondrial bioenergetics. Engineered nanomaterial exposure to the pregnant mother may interfere with fetal development and have acute and long-term cardiovascular consequences for the fetal pup that persist into adulthood. We are evaluating the impact of exposure to a number of nanomaterials (nano-TiO₂, graphene, multi-walled carbon nanotubes).

In addition, particulate matter exposure generated by crustal material resulting from surface mining (mountaintop mining) which is prevalent in Appalachia, is associated with increased cardiovascular disease incidence. Our laboratory and others have reported extrapulmonary effects to cardiac and mitochondrial dysfunction following acute pulmonary exposure to particulate matter collected from sites proximal to active mountaintop mining operations in southern West Virginia. Extrapulmonary effects of mountaintop mining particulate matter exposure is an active research priority for residents of Appalachia. Collaborations with the WVU School of Public Health and the local National Institute of Occupational Safety and Health (NiOSH) enable us to translate personal and occupational exposures of potentially toxic stressors into animal models, and determine the impact these particles may have on cardiac contraction and mitochondrial function.

Training Environment

The training environment in the Hollander Laboratory provides an opportunity for students and postdoctoral researchers to experience a broad array of techniques, skills and models. Numerous experimental models are utilized to explore biological questions and include cell culture systems, mammalian models of disease, human patient samples of clinical and disease relevance, and human induced pluripotent stem cells. Laboratory personnel participate in experiments that utilize molecular biology, biochemistry, physiology, and bioinformatic approaches. Cardiac contractile functional analyses are a particular focus in both in vivo and in utero settings.

Laboratory staff participate in the generation of novel genetically-modified rodent models. The goal is to provide a training environment that facilitates a broadening of knowledge and skillset to increase competitiveness for future positions and employment. The cutting-edge techniques coupled with nature of the research topics provide students with a strong opportunity for independent research funding with institutions (National Institutes of Health) and private associations (American Heart Association).

Grants and Research

Current Grants and Contracts

• American Heart Association, Great National, 4/1/21 - 3/31/23 (Direct Costs: $63,040)
  • Role: Sponsor (PI: A. Taylor)
  • "Long Non-Coding RNA Preservation of Cardiac Function Through Regulation of microRNA Activity Within Mitochondria." The goal of these studies is to determine how long non-coding RNAs regulate the mitochondrial genome via microRNA interactions.
• NIH R01, National Institute of Environmental Health and Safety, 8/28/13 - 8/27/22 (Direct Costs: $1,250,000)
  • Role: Collaborating Investigator (PI: T. Nurkiewicz)
  • “Maternal Nanomaterial Exposures: Fetal Microvascular Endpoints and Programming.” The goal of these studies is to understand the impact of engineered nanomaterial exposures on microvascular function in progeny exposed in utero.
• Whipkey Diabetes Mellitus Endowment, Community Foundation for the Ohio Valley, Whipkey Estate, 7/1/21 - 6/30/22 (Direct Costs: $125,000)
  • “WVU HSC - Whipkey Trust Partnership.” These funds are an endowment that is used to support the mission of the WVU Mitochondria, Metabolism & Bioenergetics Working Group for which Dr. Hollander serves as the Director. This is a yearly endowment that is renewed annually.

Completed Grants and Contracts

PI unless otherwise stated

• American Heart Association, Great National, 1/1/20 - 12/31/21 (Direct Costs: $53,688)
  • Role: Sponsor (PI: A. Kunovac)
  • "Cardiac Epitranscriptomic and Mitochondrial Remodeling in Progeny Following Maternal Engineered Nanomaterial Exposure." The goal of these studies was to determine how cardiac mitochondrion is impacted by nanotoxicological insult during gestation and mechanistic role of the epigenome.
• NIH R01, National Heart, Lung and Blood Institute, 4/1/17 - 10/31/21 (Direct Costs: $899,945)
  • “MicroRNA Regulation of the Mitochondrial Genome.” The goal of these studies was to determine how mitochondrial microRNAs are regulated in diabetic human myocardium.
• NIH R25, National Heart, Lung and Blood Institute, 9/1/16 - 8/31/21 (Direct Costs: $389,310)
  • Role: Mentor
  • “The Summer Pharmacy Experiences in Academic Research (SPEAR) Program at Hampton University School of Pharmacy.” The overall goal of this training program was to foster desire in minority students to pursue a future in health-related research following graduation from pharmacy school.
• NIH R15, National Institute of Environmental Health and Safety, 8/14/17 - 8/13/21 (Direct Costs: $300,000)
  • Role: Collaborating Investigator
  • “PM2.5 from Fracking Operations Induces Microvascular and Mitochondrial Dysfunction.” The goal of these studies was to determine the impact of ultrafine particulate matter arising from fracking operations on microvascular and mitochondrial functional endpoints. 
• Whipkey Diabetes Mellitus Endowment, Community Foundation for the Ohio Valley, Whipkey Estate, 7/1/19 - 6/30/21 (Direct Costs: $100,000)
  • “WVU HSC - Whipkey Trust Partnership.” These funds are an endowment that is used to support the mission of the WVU Mitochondria, Metabolism & Bioenergetics Working Group for which Dr. Hollander serves as the Director. This is a yearly endowment that is renewed annually.
• NIH K99, National Institute of Environmental Health and Safety, 2/1/15 - 1/31/20 (Direct Costs: $513,717)
  • Role: Consultant (PI: P. Stapleton)
  • “Mitochondrial Mechanisms, Microvascular Dysfunction and Gestational Nanotoxicology.” The goal of these studies was to determine how the mitochondrion in the vasculature is impacted by nanotoxicological insult during in utero exposure.
• WVU INBRE Next Generation Sequencing Grant, WVU INBRE IDEA, 8/1/18 - 7/31/19 (Direct Costs: $20,000)
  • “Next Generation Sequencing of Human Endogenous Cardiac Stem Cells in the Human Diabetic Heart.” The goal of these studies was to determine the mRNA and miRNA sequences of RISC bound mitochondrial genome encoded mRNAs in isolated mitochondria subpopulations using a HiSeq platform.
• American Heart Association, Great Rivers Affiliate, 8/1/17 - 7/31/19 (Direct Costs: $53,688)
  • Role: Sponsor (PI: Q. Hathaway)
  • “Mitochondrial microRNA Import and Regulation.” The goal of these studies was to determine the mechanisms regulating microRNA import into the mitochondrion and identify epigenetic mechanisms driving the process.
• Whipkey Diabetes Mellitus Endowment, Community Foundation for the Ohio Valley, Whipkey Estate, 7/1/18 - 6/30/19 (Direct Costs: $118,000)
  • “WVU HSC - Whipkey Trust Partnership.” These funds are an endowment that is used to support the mission of the WVU Mitochondria, Metabolism & Bioenergetics Working Group for which Dr. Hollander serves as the Director. This is a yearly endowment that is renewed annually.
• NIH R21, National Institute on Aging, 4/1/17 - 3/31/19 (Direct Costs: $275,000)
  • Role: Collaborating Investigator (PI: Q. Chen)
  • “Activation of Mitochondrial Calpain Augments Cardiac Injury in Aged Hearts.” The goal of these studies was to understand the mechanisms driving campaigns impact in the injured and aged heart with a focus on proteomic signature.
• NIH R56, National Heart, Lung and Blood Institute, 9/8/15 - 8/31/18 (NCE) (Direct Costs: $274,662)
  • “MicroRNA Regulation of the Mitochondrial Genome.” The goal of these studies was to determine how mitochondrial microRNAs are regulated in diabetic human myocardium.
• Whipkey Diabetes Mellitus Endowment, Community Foundation for the Ohio Valley, Whipkey Estate, 3/1/17 - 2/28/18 (Direct Costs: $110,000)
  • “WVU HSC - Whipkey Trust Partnership.” These funds are an endowment that is used to support the mission of the WVU Mitochondria, Metabolism & Bioenergetics Working Group for which Dr. Hollander serves as the Director. This is a yearly endowment that is renewed annually.
• IGERT Training Fellowship, National Science Foundation, 8/15/15 - 7/31/17 (Direct Costs: $150,000)
  • Role: Sponsor (PI: Q. Hathaway)
  • “Impact of Environmental Toxicity on Cardiac Function and Metabolism.” The goal of these studies was to determine the impact of environmental particulate exposure on cardiac function and metabolism while training the student in key research areas.
• Clinical Pilot Funding Award, West Virginia Clinical and Translational Science Institute, 7/1/14 - 7/1/16 (Direct Costs: $75,000)
  • “Therapeutic Manipulation of Mitochondrial Protein Import in the Type 2 Diabetic Patient Heart.” The goal of these experiments was to test the potential therapeutic influence of manipulating the mitochondrial protein import system in type 2 diabetic patient tissue.
• American Heart Association, Great Rivers Affiliate, 7/1/13 - 6/30/15 (Direct Costs: $52,000)
  • Role: Sponsor (PI: C. Nichols)
  • “Influence of Engineered Nanomaterial Inhalation on Cardiac Mitochondria.” The goal of these studies was to determine the impact of nano-TiO₂ exposure on cardiac mitochondria utilizing transgenic mouse models.
• American Heart Association, Great Rivers Affiliate, 7/1/14 - 6/30/15 (Direct Costs: $26,000)
  • Role: Sponsor (PI: D. Shepherd)
  • “Human and Mouse Type 2 Diabetes Mellitus and the Mitochondrial Proteome:  The Beginning to Therapeutic Possibilities.” The goal of these studies was to determine the impact of type 2 diabetes mellitus on the mitochondrial proteome in mouse and patient models.
• Research Funding and Development Grant, West Virginia University School of Medicine, 4/1/14 - 3/31/15 (Direct Costs: $25,000)
  • “miRNA Regulation of the Mitochondrial Genome During Diabetes Mellitus.” The goal of these experiments was to determine the impact of diabetes mellitus on the regulation of the mitochondrial genome through miRNA interaction.
• NIH DCC Pilot Award, National Institute of Diabetes, Digestive and Kidney Diseases, 11/1/13 - 10/31/14 (Direct Costs: $60,000)
  • “MicroRNA Regulation in the Type 2 Diabetic Human Heart.” The goal of these studies was to determine the presence and contribution of mitochondrial microRNAs in human cardiac tissue from type 2 diabetic patients.
• Graduate Training Grant (T32HL090610), NIH, National Heart, Lung and Blood Institute, 8/1/08 - 10/31/14
  • Role: Sponsor Mentor (PI: S. Mustafa)
  • “Research Training in Cardiovascular and Pulmonary Diseases.” The goal of this grant was to provide meritorious research and academic training for graduate students interested in pursuing research careers in the area of cardiovascular and pulmonary diseases.
• NIH R15, National Institutes on Aging, 8/8/11 - 6/30/14 (Direct Costs: $300,000)
  • Role: Consultant (PI: K. Huey, Drake University)
  • “VEGF and Skeletal Muscle Adaptation During Chronic Overload.” The goal of these studies was to discern the impact of aging on VEGF and heat shock protein 25 in skeletal muscle.
• SFRBM Research Mini-Fellowship, Society for Free Radical Biology and Medicine, 1/1/13 - 12/31/13 (Direct Costs: $2,500)
  • Role: Collaborating Investigator (PI: F. Rouen)
  • “Genomic and Non-genomic Roles of STAT 3.” The goal of these studies was to determine the genomic and non-genomic roles of STAT 3 and its regulation on reactive oxygen species.
• N30 Pharmaceuticals, 11/1/11 - 12/31/13 (Direct Costs: $6,000)
  • “Evaluation of Nitrosoglutathione and its Metabolites in Lung Mitochondria.” The goal of these studies was to determine the presence of nitrosoglutathione and its metabolites in isolated mitochondria.
• WVU Genomics Next Generation Sequencing Grant, WVU Genomics Facility, 8/31/12 - 10/31/13 (Direct Costs: $4,000)
  • “Evaluation of Small RNAs in Mitochondrial Subpopulations.” The goal of these studies was to determine the mRNA and miRNA sequences of RISC bound mitochondrial genome encoded mRNAs in isolated mitochondria subpopulations using a MiSeq platform.
• WVU INBRE Next Generation Sequencing Grant, WVU INBRE IDEA, 10/3/12 - 10/2/13 (Direct Costs: $10,000)
  • “Evaluation of Small RNAs in Mitochondrial Subpopulations.” The goal of these studies was to determine the mRNA and miRNA sequences of RISC bound mitochondrial genome encoded mRNAs in isolated mitochondria subpopulations using a HiSeq platform.
• NIH DP2, Director’s New Innovator Award, Type 1 Diabetes Pathfinder Award, National Institute of Diabetes, Digestive and Kidney Diseases, 9/30/08 - 8/31/13 (Direct Costs: $1,500,000)
  • “Mechanisms of Diabetic Cardiomyopathy: Mitochondria Subpopulations Brought to Focus.” The goal of these studies is to design therapeutic interventions targeted to mitochondria that will aid in the treatment of type 1 diabetes mellitus.
• NIH K99, National Institute on Aging, 9/1/08 - 8/31/13 (Direct Costs: K-Series Award)
  • Role: Consultant (PI: B. Behnke)
  • “Vascular Structure and Function with Aging, Viral Gene Therapy, and Exercise Training.” The goal of these studies was to test the broad hypothesis that aging induces microcirculatory dysfunction (both structural and functional) that impairs oxygen transport, and exercise training can attenuate this microcircular dysfunction.
• IGERT Training Fellowship, National Science Foundation, 8/15/12 - 8/14/13 (Direct Costs: $60,000)
  • Role: Sponsor (PI: C. Nichols)
  • “Acute Inhalation Exposure of Nano-Titanium Dioxide.” The goal of these studies was to determine the impact of nano-titanium dioxide on mitochondrial disposition.
• WVU Bridge Grant, WVU Research Corporation, 1/1/12 - 12/31/12 (Direct Costs: $25,000)
  • “Diabetic Mitochondrial Dysfunction.” The goal of these studies was to determine the impact of type 1 diabetic insult on cardiac mitochondrial protein import machinery and generate preliminary data for an NIH R01 resubmission.
• American Heart Association, Great Rivers Affiliate, 7/1/10 - 6/30/12 (Direct Costs: $42,000)
  • Role: Sponsor (PI: W. Baseler)
  • “Examination of Protein Import in Mitochondria Influenced by Diabetes Mellitus in the Heart.” The goal of these studies was to determine the impact of type 1 diabetic insult on the mitochondrial import process in the heart.
• American Heart Association Beginning Grant-In-Aid, American Heart Association, Great Rivers Affiliate, 7/1/10 - 6/30/12 (Direct Costs: $121,000)
  • Role: Collaborating Investigator (PI: I.M. Olfert)
  • “Smoking and Thrombospondin-1 (TSP-1) Regulation of Skeletal Muscle Microvasculature.” The goal of these studies was to determine the impact of cigarette smoke TSP-1 on the skeletal muscle microvasculature density and function.
• American Heart Association Beginning Grant-In-Aid, American Heart Association, Great Rivers Affiliate, 7/1/09 - 6/30/11 (Direct Costs: $121,000)
  • Role: Collaborating Investigator (PI: M. Morissette)
  • “Cardiac-Specific Inhibition of Myostatin in Hypertrophy of the Adult and Aging Heart.” The goal of these studies was to determine the role of myostatin inhibition in the aged and adult heart.
• NIH DP2, Director’s New Innovator Award, Type 1 Diabetes Pathfinder Award (Administrative Supplement), 1/1/10 - 9/30/10 ($85,000)
  • “Mechanisms of Diabetic Cardiomyopathy: Mitochondria Subpopulations Brought to Focus.” The goal of these studies was to design therapeutic interventions targeted to mitochondria that will aid in the treatment of type 1 diabetes mellitus. The goal of the supplement is to provide equipment for infrastructure.
• NIH DP2, Director’s New Innovator Award, Type 1 Diabetes Pathfinder Award (Travel Supplement), 1/1/10 - 9/30/10 ($1,500)
  • “Mechanisms of Diabetic Cardiomyopathy: Mitochondria Subpopulations Brought to Focus.” The goal of these studies was to design therapeutic interventions targeted to mitochondria that will aid in the treatment of type 1 diabetes mellitus. The goal of the supplement was to provide for travel to the NIDDK New Principal Investigators Workshop.
• NIH P30, National Cancer Institute, 1/1/10 - 9/30/10 (Direct Costs: $500,000)
  • Role: Project Leader (PI: K. Martin)
  • “Shared Instrumentation: In Vivo Ultrasound.” The goal of this grant was to obtain a Vevo 2100 ultrasound machine. The goal of Dr. Hollander’s project was to utilize the piece of equipment for cardiac contractile analyses in diabetic mice as well as genetically-altered diabetic mice.
• American heart Association Grant-In-Aid, American Heart Association, Great Rivers Affiliate, 7/1/08 - 6/30/10 (Direct Costs: $121,000)
  • “Mitochondrial Subpopulation Response to Ischemia/Reperfusion Injury: Influence of mPHGPX Overexpression.” The goal of these studies was to determine the differential response of mitochondria populations to ischemia/reperfusion injury, and determine the efficacy of mPHGPx overexpression.
• American Heart Association Predoctoral Fellowship, American Heart Association, Great Rivers Affiliate, 7/1/08 - 6/30/10 (Direct Costs: $42,000)
  • Role: Sponsor (PI: E. Dabkowski)
  • “Influence of a Diabetic Phenotype on Specific Mitochondrial Subpopulations in the Heart.” The goal of these studies was to determine the differential response of mitochondria populations to diabetic insult, and determine the efficacy of mPHGPx overexpression.
• Research Funding and Development Grant, West Virginia University School of Medicine, 7/1/09 - 6/30/10 (Direct Costs: $25,000)
  • Role: Collaborating Investigator (PI: M. Morissette)
  • “Cardiac-Specific Inhibition of Myostatin in Hypertrophy of the Adult and Aging Heart.” The goal of these experiments was to determine the impact on cardiac function of heat shock protein 25 removal in various cell types, using a novel conditional knockout animal generated by the PI.
• American heart Association Grant-In-Aid, American Heart Association, 7/1/06 - 6/30/08 (Direct Costs: $121,000)
  • “Myocardial Protection from I/R Injury by mPHGPx Overexpression.” The goal of these experiments was to determine the impact adenoviral transgene delivery of mPHGPx overexpression on cardiac function during ischemia/reperfusion insult.
• Amyotrophic Lateral Sclerosis Association Research Grant, ALS Society, 2/1/07 - 1/31/08 (Direct Costs: $40,000)
  • Role: Collaborating Investigator (PI: M. Gunther)
  • “Mutant Superoxide Dismutase-Induced Mitochondrial Defects.” The goal of these experiments was to determine the impact of SOD2 on mitochondrial defects associated with ALS. My role as Collaborating Investigator was to generate adenoviral particles expressing SOD2 and specific mutant SOD2 proteins that are targeted to the mitochondrion to gain insight into their effect on disease progression.
• Research Funding and Development Grant, West Virginia University School of Medicine, 1/1/07 - 12/31/07 (Direct Costs: $25,000)
  • “Cell-Type Specific Removal of Hsp25 in the Diabetic Heart.” The goal of these experiments was to determine the impact on cardiac function of heat shock protein 25 removal in various cell types, using a novel conditional knockout animal generated by the PI.
• Research Funding and Development Grant, West Virginia University School of Medicine, 1/1/06 - 12/31/06 (Direct Costs: $25,000)
  • “Mitochondrial Protection from I/R Injury by mPHGPx Overexpression.” The goal of these experiments was to determine the impact adenoviral transgene delivery of mPHGPx overexpression on cardiac function during ischemia/reperfusion insult.
• Minority Investigator Research Supplement (MIRS), NIH, National Heart, Lung and Blood Institute, 1/1/05 - 7/1/05 (Direct Costs: $110,000)
  • “Cardiac Ischemia and Heat Shock Proteins.” The goal of these experiments was to determine the combinatorial effect of adenoviral overexpression of multiple heat shock protein constructs, on protection from ischemia/reperfusion insult.

Publications

Recent Publications in Refereed Journals

1. Durr AJ, Hathaway QA, Kunovac A, Taylor AD, Pinti MV, Rizwan S, Shepherd DL, Cook CC, Fink GK, Hollander JM. Manipulation of the miR-378a/mt-ATP6 regulatory axis rescues ATP synthase in the diabetic heart and offers a novel role for lncRNA Kcnq1ot1. Am J Physiol Cell Physiol. 2022 Mar 1;322(3):C482-C495. PMID: 35108116. Awarded APS Select status as a top published article in physiological research.
2. Kunovac A, Hathaway QA, Pinti MV, Durr AJ, Taylor AD, Goldsmith WT, Garner KL, Nurkiewicz TR, Hollander JM. Enhanced antioxidant capacity prevents epitranscriptomic and cardiac alterations in adult offspring gestationally-exposed to ENM. Nanotoxicology. 2021 Aug;15(6):812-831. PMID: 33969789
3. Kunovac A, Hathaway QA, Pinti MV, Taylor AD, Hollander JM. Cardiovascular adaptations to particle inhalation exposure: Molecular mechanisms of the toxicology. Am J Physiol Heart Circ Physiol. 2020 Aug 1;319(2):H282-H305. PMID: 32559138
4. Kunovac A, Hathaway QA, Pinti MV, Goldsmith WT, Durr AJ, Fink GK, Nurkiewicz TR, Hollander JM. ROS promote epigenetic remodeling and cardiac dysfunction in offspring following maternal engineered nanomaterial (ENM) exposure. Part Fibre Toxicol. 2019 June 18;16(1):24. PMID: 31215478
5. Hathaway QA, Roth SM, Pinti MV, Sprando DC, Kunovac A, Durr AJ, Cook CC, Fink GK, Cheuvront TB, Grossman JH, Aljahli GA, Taylor AD, Giromini AP, Allen JL, Hollander JM. Machine-learning to stratify diabetic patients using novel cardiac biomarkers and integrative genomics. Cardiovasc Diabetol. 2019 June 11;18(1):78. PMID: 31185988. Featured in BBC Future.
6. Geldenhuys WJ, Long TE, Saralkar P, Iwasaki T, Nuñez RAA, Nair RR, Konkle ME, Menze MA, Pinti MV, Hollander JM, Hazlehurst LA, Robart AR. Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand. Commun Chem. 2019;2:77. PMID: 32382661
7. Hathaway QA, Durr AJ, Shepherd DL, Pinti MV, Brandebura AN, Nichols CE, Kunovac A, Goldsmith WT, Friend SA, Abukabda AB, Fink GK, Nurkiewicz TR, Hollander JM. miRNA-378a as a key regulator of cardiovascular health following engineered nanomaterial inhalation exposure. Nanotoxicology. 2019 Jun;13(5):644-663. PMID: 30704319
8. Shepherd DL, Hathaway QA, Nichols CE, Durr AJ, Pinti MV, Hughes KM, Kunovac A, Stine SM, Hollander JM. Mitochondrial proteome disruption in the diabetic heart through targeted epigenetic regulation at the mitochondrial heat shock protein 70 (mtHsp70) nuclear locus. J Mol Cell Cardiol. 2018 Jun;119:104-115. PMID: 29733819
9. Hathaway QA, Pinti MV, Durr AJ, Waris S, Shepherd DL, Hollander JM. Regulating microRNA expression: At the heart of diabetes mellitus and the mitochondrion. Am J Physiol Heart Circ Physiol. 2018 Feb 1;314(2):H293-H310. PMID: 28986361
10. Nichols CE, Shepherd DL, Hathaway QA, Durr AJ, Thapa D, Abukabda A, Yi J, Nurkiewicz TR, Hollander JM. Reactive oxygen species damage drives cardiac and mitochondrial dysfunction following acute nano-titanium dioxide inhalation exposure. Nanotoxicology. 2018 Feb;12(1):32-48. PMID: 29243970

Recent Presentations

1. Hathaway QA, Yanamala N, Patel HB, Siva NK, Kagiyama N, Hollander JM, Sengupta PP. Morphometric patterning of acoustic texture parameters for rapid screening of cardiac remodeling using point-of-care ultrasound imaging. American Society of Echocardiography 32nd Annual Scientific Sessions. Virtual. 2021 Jun.
2. Kunovac A, Burrage E, Coblentz T, Kelley E, Sengupta P, Hollander JM, Hathaway QA, Chantler PC. Identifying unique patters of myocardial deformation through segmental speckle tracking stress strain following high-fat diet. Experimental Biology National Conference. Virtual. 2021 Apr.
3. Hathaway QA, Majumder N, Kunovac A, Xie Z, Pinti MV, Harkema JR, Nurkiewicz T, Hollander JM, Hussain S. Modeling the pulmonary transcriptome in a dose-dependent manner: Carbon black and ozone co-exposure. Society of Toxicology National Conference. Virtual. 2021 Mar.
4. Hathaway QA, Roth SM, Pinti MV, Sprando DC, Kunovac A, Durr AJ, Cook CC, Fink GK, Cheuvront T, Grossman J, Aljahli G, Taylor AD, Giromini A, Allen J, Hollander JM. Applying machine-learning to disease diagnosis through patient-matched omics profiles. Mitochondrial Biology Symposium. Bethesda, MD. 2020.
5. Taylor AD, Hathaway QA, Kunovac A, Pinti MV, Cook CC, Fink GK, Durr AJ, Shepherd DL, Robart AR, Hollander JM. Impact of diabetes mellitus on mitochondrial miRNA diversity and related cellular pathways. Mitochondrial Biology Symposium. Bethesda, MD. 2020.
6. Kunovac A, Hathaway QA, Durr AJ, Goldsmith WT, Taylor AD, Pinti MV, Fink GK, Nurkiewicz TR, Hollander JM. Antioxidant protection attenuates cardiac and mitochondrial dysfunction in offspring following maternal engineered nanomaterial exposure. Mitochondrial Biology Symposium. Bethesda, MD. 2020.
7. Durr AJ, Hathaway QA, Taylor AD, Kunovac A, Pinti MV, Shepherd DL, Fink GK, Hollander JM. Loss of microRNA-378a function restores mitochondrial bioenergetics in a type 2 diabetic mouse model. Mitochondrial Biology Symposium. Bethesda, MD. 2020.